Tri Pointe Homes' lower P/E ratio may reflect investors' skepticism about its earnings performance improvement. Despite forecasted growth aligning with the market, its P/E ratio lags, indicating shareholders' doubt over forecasts and acceptance of lower selling prices.
The lack of recent insider transactions at Tri Pointe Homes isn't worrying. However, the past year's insider transactions aren't encouraging. The level of insider ownership suggests some alignment between management and smaller shareholders.
Tri Pointe Homes' lower growth forecast compared to the market justifies investors' lower price willingness, reflected in its P/E ratio. Impending share price increase appears unlikely due to these factors.
Insider selling at Tri Pointe Homes raises questions about their perception of the recent high valuation. However, the level of insider ownership still indicates alignment with shareholder interests.
Tri Pointe Homes' stable ROCE and alignment with industry average doesn't project it as a future multi-bagger due to its lack of reinvestment. Its trend of stable returns on the same capital over 5 years signals a limited likelihood of it becoming a multi-bagger.
The analysts' predictions suggest a potential uptrend for several home builders, showing particularly strong confidence in PulteGroup, Toll Brothers, and Tri Pointe.
TRIポイント・ホームズに関するコメント
コラムTop upgrades and downgrades on 6/16: BA, DG, U, WSO and more
• $アカディア・ファーマシューティカルズ(ACAD.US)$ : Jefferies Upgrades to Buy from Hold - PT $25 (from $22)
• $アーサーJ.ギャラガー(AJG.US)$ : RBC Capital Upgrades to Outperform from Sector Perform - PT $185 (from $182)
• $アップル・ホスピタリティ・リート(APLE.US)$ : B.Riley Upgrades to Buy from Neutral - PT $19
• $オートゾーン(AZO.US)$ : Morgan Stanley Upgrades to Overweight from Equalweight - PT $2,420 (from $2,125)
• $ボーイング(BA.US)$ : Citigroup Upgr...
コラムToday's pre-market stock movers: AMZN, AAPL, MA, CVX and more
• $GTY Technology(GTYH.US)$ +118.1% (entered into a definitive agreement to be acquired by GI Partners )
• $フィンチ・セラピューティクス(FNCH.US)$ +68.33% (announces removal of FDA clinical hold on CP101 IND)
• $ザイムワークス(ZYME.US)$ +42.34% (confirms receipt of non-binding proposal from All Blue Falcons for $10.50 per share in cash)
• $ハブ・グループ(HUBG.US)$ +16.3% (earnings reports)
• $ランセウス・ホールディングス(LNTH.US)$ +14.2% (earnings reports)
• $モホーク・インダストリーズ(MHK.US)$ +13.7% (e...
まだコメントはありません